Virtual Dialogue 4: Moving Forward

Anthony P. Conley, M.D. Associate Professor of the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, TX. and Principal Investigator for the Phase 2 Clinical trials for INBRX-109 reviewed the clinical trials he conducted using INBRX-109. The medication was recently granted orphan-drug designation by the FDA to treat conventional chondrosarcoma. Dr. Conley also discussed the future role medications like INBRX-109 will have in treating Chondrosarcoma.

William Cross, PhD. a Research Fellow in the Department of Research Pathology, UCL Cancer Institute in London addressed his research findings of genetic mutations found in chondrosarcoma cells that may have direct implications for patient outcome. People with specific mutation combinations (in the genes IDH1 and TERT) do worse, hence they should be given more attention upfront. He discusses the need for testing the presence of these biomarkers following diagnosis, which is done for other cancer types and is cost effective in the modern oncology clinic.

Janet Mauro, BA, CCRC, Research Programs Associate, Regulatory Affairs at the National Organization for Rare Disorders, Inc. (NORD®) discusses the NORD: IAMRARE® Patient Registry Platform, and identifies the benefits of implementing a Patient Registry / Natural History Study, the type of information collected and how patient-entered data can be used to advance research and treatment. Ms. Mauro also addresses concerns about security, privacy, confidentiality and other relevant issues.